Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 14, 2024
Since its inception, DFC has demonstrated its capacity to rapidly increase its investment volume, making use of a higher portfolio cap. Its annual commitments have doubled over the past four years. But the agency has been subject to criticism (including from some at CGD) for insufficiently prioritiz...
Blog Post
August 30, 2023
There’s a representation problem in the fields of economics and research that has been well documented. As my colleagues have written about previously here and here, studies have shown that only 5 percent of papers in top journals study low- and middle-income countries (LMIC), and research output is...
Blog Post
August 28, 2023
We’d been eagerly awaiting an update to DFC’s downloadable project data for insight into the development finance agency’s recent investments and overarching portfolio composition. A new drop finally came earlier this month detailing transactions through FY2022 and timed with the release of DFC’s ina...
Blog Post
July 27, 2023
Last week’s Senate Appropriations Committee markup revealed a vast gulf dividing the Capitol with respect to development and diplomacy funding for the coming fiscal year. The two chambers’ State and Foreign Operations spending bill toplines are more than $9 billion apart, with the House coming in at...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Blog Post
January 10, 2023
Ahead of the holiday break, US lawmakers reached agreement on a final FY2023 spending deal. After months of stalled negotiations, an omnibus appropriations package was far from guaranteed. But concerns about the consequences of a long-term continuing resolution—and the prospect of adding a major tas...
CGD NOTES
December 14, 2022
Ensuring rapid and equitable access to effective oral COVID-19 therapies is essential to reducing health disparities from COVID-19 and building a better response system for future epidemics and pandemics. A multipronged strategy for medical countermeasures must include antivirals, monoclonal antibod...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.